MedTrace Logo

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

NCT01316237 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2012-03-26

No results posted yet for this study

Summary

A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects with Chronic Hepatitis C Virus Infection.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

GS-6620

GS-6620 tablet, 50 mg QD

DRUG

GS-6620

GS-6620 tablet, 100 mg QD

DRUG

GS-6620

GS-6620 tablet, 300 mg QD

DRUG

GS-6620

GS-6620 tablet, 100 mg QD, Fasted

DRUG

GS-6620

GS-6620 tablet, 300 mg QD, Fasted

DRUG

GS-6620

GS-6620 tablet, 900 mg QD, Fasted

DRUG

GS-6620 tablet, 450 mg BID

GS-6620 tablet, 450 mg BID

DRUG

GS-6620 tablet

GS-6620 tablet, 900mg , BID

DRUG

GS-6620 tablet

GS-6620 tablet, 900 mg

Sponsors & Collaborators

Principal Investigators

  • Stephen Rossi, PharmD · Gilead Sciences

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-10-31
Completion
2012-01-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01316237 on ClinicalTrials.gov